Cargando…
Active surveillance for prostate cancer: when to recommend delayed intervention
There are no agreed upon guidelines for placing patients on active surveillance (AS). Therefore, there are no absolute criteria for taking patients off AS and when to recommend treatment. The criteria used to define progression are currently based on prostate specific antigen (PSA) kinetics, biopsy...
Autor principal: | Babaian, Kara N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814954/ https://www.ncbi.nlm.nih.gov/pubmed/26178391 http://dx.doi.org/10.4103/1008-682X.151396 |
Ejemplares similares
-
Active surveillance monitoring: the role of novel biomarkers and imaging
por: Ward, John F, et al.
Publicado: (2015) -
The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer
por: Xu, Jianfeng
Publicado: (2014) -
Perspectives on the clinical management of localized prostate cancer
por: Nelson, Joel B
Publicado: (2014) -
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015) -
Optimal management of prostate cancer with lethal biology – state-of-the-art local therapy
por: Chapin, Brian F
Publicado: (2015)